Lead Product(s) : Remestemcel-L
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : In the COVID-19 ARDS trial of Remestemcel-L significantly reduced mortality by 48% at 90 days compared to controls in a pre-specified analysis of 123 treated patients under 65 years old.
Product Name : Ryoncil
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
July 19, 2021
Lead Product(s) : Remestemcel-L
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Curcumin,Boswellia Serata
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MGC Pharma has secured this import license from CDSCO for CimetrA to enable it to submit final samples of CimetrA for testing and analysis. CimetrA is a nanoparticle micellar formulation based on a synergetic composition consisting of Curcumin and Boswel...
Product Name : CimetrA
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 09, 2021
Lead Product(s) : Curcumin,Boswellia Serata
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Remestemcel-L
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The protocol was filed with the United States Food and Drug Administration (FDA) and provides physicians with access to remestemcel-L for an intermediate-size patient population1 under Mesoblast’s existing Investigational New Drug (IND) application.
Product Name : Ryoncil
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
June 07, 2020
Lead Product(s) : Remestemcel-L
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable